Competitive AMPA antagonism: A novel mechanism for antiepileptic drugs?

Drugs of the Future

Volumn 26, Issue 5, 2001, Pages 463-471

  Auberson, Y P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 (4 DIMETHYLSULFAMOYLPHENYL) 6,7,8,9 TETRAHYDRO 8 METHYL 2 OXO 1H PYRROLO[3,2 H]ISOQUINOLIN 3 YLIMINOXY] 4 HYDROXYBUTYRIC ACID; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; [[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID; AMP 397A; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; INDENONE 1; INDENONE 4F; ISATIN DERIVATIVE; LU 112313; LU 115455; NS 229; NS 257; PENTOBARBITAL; QUINOXALINE DERIVATIVE; S 16678; S 17625; THIOBARBITAL; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ABSENCE; ANTICONVULSANT ACTIVITY; BINDING AFFINITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EPILEPSY; NONHUMAN; RAT; RECEPTOR BLOCKING; REFLEX EPILEPSY; REVIEW; STRUCTURE ANALYSIS;

EID: 0034912154     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.05.659545     Document Type: Review

References (87)

1. Early identification of refractory epilepsy
2. The impact of epilepsy from the patient's perspective I. Description subjective perceptions
3. The impact of epilepsy from the patient's perspective II. Views about therapy health care
4. Glutamate receptors in epilepsy
5. The excitatory amino acid antagonist D-CPPene (SDZ EAA-494) in patients with epilepsy
6. Clinical experience with excitatory amino acid antagonist drugs
7. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans
8. Effects of the 2-amino-3-hydroxy-5-methyl-isoxazole-propionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain
9. A crucial role of the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype of glutamate receptors in piriform and perirhinal cortex for the initiation and propagation of limbic motor seizures
10. Acute effect of various GABA receptor agonists and glutamate antagonists on focal hippocampal seizures in freely moving rats elicited by low-frequency stimulation
11. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy
12. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs
13. Mechanism of anticonvulsant agents
14. Use-dependent pentobarbital block of kainate and quisqualate currents
15. Sensitivity of AMPA receptors to pentobarbital
16. Comparison of the effects of convulsant and depressant barbiturate stereoisomers on AMPA-type glutamate receptors
17. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action
18. Cellular actions of topiramate: Blockade of kainate-evoked inward currents in cultured hippocampal neurons
19. Topiramate blocks kainate-evoked cobalt influx into cultured neurons
20. Actions of sodium valproate on the central nervous system
21. Valproate enhances GABA-A mediated inhibition of locus coeruleus neurons in vitro
22. 3H]α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA] binding by the anticonvulsant valproate in clinically relevant concentrations: An autoradiographic investigation in human hippocampus
23. Screening of new compounds and the role of the pharmaceutical industry
24. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs
25. Kindling: Basic mechanisms clinical validity
26. Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation?
27. Relevance of kindling and related processes to human epileptogenesis
28. Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs
29. Effects of YM90K, a selective AMPA receptor antagonist, on amygdala-kindling and long-term hippocampal potentiation in the rat
30. A new pyrrolylquinoxalinedione series of non-NMDA glutamate receptor antagonists: Pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy
31. Anticonvulsant activity of AMPA/kainate antagonists: Comparison of GYKI 5 2466 and NBQX in maximal electroshock and chemoconvulsant seizure models
32. Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]indeno[1,2-e]pyrazin-8- and -9-carboxylic (acetic) acid AMPA antagonists
33. Phosphonate quinoxalinedione AMPA antagonists
34. Scope and contribution of genetic models to an understanding of the epilepsies
35. Evaluation of anticonvulsant drugs in DBA/2 mice with sound-induced seizures
36. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice
37. Structure-activity relationships in a series of 2[1H]-quinolones bearing different acidic function in the 3-position: 6,7-Dichloro-2[1H]-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties
38. YM90K: Pharmacological characterization as a selective, potent α-amino-4-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist
39. Neurobiology of seizure predisposition in the genetically epilepsy-prone rat
40. The genetically epilepsy-prone rat. An overview of seizure-prone characteristics and responsiveness to anticonvulsant drugs
41. The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two models of reflex epilepsy
42. Photosensitive epilepsy in Papio papio as a model of drug studies
43. Photosensitivity as a model for acute antiepileptic drug studies
44. Spontaneous paroxysmal electroclinical patterns in rats: A model of generalized nonconvulsive epilepsy
45. Are rats with genetic absence epilepsy behaviorally impaired?
46. Genetic absence epilepsy rats from Strasbourg: A review
47. Human absence epilepsy: The WAG/Rij rat as a model
48. The WAG/Rij model for absence epilepsy: Anticonvulsant drug evaluation
49. The WAG/Rij rat model for nonconvulsive absence epilepsy: Involvement of non-NMDA receptors
50. AMP397A: Novel, broad-spectrum anticonvulsant with potential benefit for therapy-resistant epileptic patients
51. AMP397A, an orally active AMPA receptor antagonist, is a broad-spectrum anticonvulsant agent
52. 2,3-Dihydro-6-nitro-7-sulfamoyl-benzo(f)quinoxaline: A neuroprotectant for cerebral ischemia
53. The NBQX story
54. ZR200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma
55. In vitro characterization of YM872, a selective, potent, highly water-soluble α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist
56. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline
57. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy
58. The effect of the non-NMDA receptor antagonists GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures
59. Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo (f)quinoxaline (NBQX)
60. Human pharmacokinetics of the neuroprotective agent NBQX
61. (3SR,4aRS,6RS,8aRS)-6-[2-(1H-Tetrazol-5-yl)ethyl]decahydroisoquinoline-3 -carb oxylic acid: A structurally novel, systemically active, competitive AMPA receptor antagonist
62. In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-[2-(1H-tetrazole-5-yl)ethyl]-decahydroisoquinoline-3- carboxylic acid
63. Isatin oximes: A novel series of bioavailable non-NMDA antagonists
64. NS 257 (1,2,3,6,7,8-hexahydro-3-(hydroximino)-N,N,7-trimethyl-2-oxobenzo[2, 1-b:3,4-c']dipyrrole-5-sulfonamide) is a potent, systemically active AMPA receptor antagonist
65. 6-(1H-Imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: Structure-activity relationships for the AMPA-type non-NMDA receptor
66. Pharmacokinetics and safety of the novel amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist YM90K in healthy men
67. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and related quinoxalinediones: Characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity
68. Design and synthesis of novel quinoxaline-2,3-dione AMPA/glyN receptor antagonists: Amino acid derivatives
69. Structure-activity relationships in a series of 3-sulfonylamino-2-(1H)-quinolones, as new AMPA/kainate and glycine antagonists
70. Pyrrolylquinoxalinediones: A new class of AMPA receptor antagonists
71. Pyrrolylquinoxalinediones: The importance of pyrrolic substitution on AMPA receptor binding
72. SPD 502: A water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity
73. Synthesis and pharmacological properties of 5H,1OH-imidazo[1,2-a]indeno-[1,2-e]pyrazine-4-one, a new competitive AMPA/KA receptor antagonist
74. 8-Methylureido-10-amino-10-methyl-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-ones: Highly in vivo potent selective AMPA receptor antagonists
75. 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: Highly potent selective AMPA receptors antagonists with in vivo activity
76. 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: Highly potent in vivo AMPA antagonists
77. N-Phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones. In vivo active AMPA NMDA(glycine) antagonists
78. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders
79. Selection of antiepileptic drug polytherapy based on mechanism of action. The evidence reviewed
80. 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice
81. Excitatory amino acid antagonists and the anticonvulsive activity of conventional antiepileptic drugs
82. Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice
83. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy
84. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats
85. 5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, systemically active and broad spectrum antagonists for NMDA/glycine, and AMPA kainate receptors
86. LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: Pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy
87. Pathophysiological mechanisms of brain damage from status epilepticus